Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact
Login Book a demo
ACT Genomics logo — Make Personalized Medicine Accessible To All.

ACT Genomics

Make Personalized Medicine Accessible To All.

Founded 2014 Taiwan Taiwan 121 employees Venture round Total: $20.50M Biotechnology, Health Care +2

General Information

Company Name ACT Genomics
Founded Year 2014
Location Taiwan Taiwan
Founders / Decision Makers
Team member Team member
Employees 121
Industries Biotechnology, Health Care, Information Technology +1
Funding Stage Venture round
Social

BounceWatch is an independent company data service, not affiliated with ACT Genomics. To contact ACT Genomics, visit actgenomics.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does ACT Genomics compare?

A PDF of ACT Genomics and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting ACT Genomics soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About ACT Genomics

ACT Genomics is a world-leading genomic test solution provider founded in 2014 and headquartered in Taiwan. The company's slogan "Make Personalized Medicine Accessible To All" reflects its commitment to providing precision medicine services globally. ACT Genomics combines tumor biology, cancer genomics, and bioinformatics expertise to offer treatment guidelines for solid tumors, relapse, drug resistance, cancer monitoring, risk assessment, and immunotherapy evaluation. The company's focus on turning every cancer patient's genetic information into actionable resolutions is supported by cutting-edge next-generation sequencing (NGS) platforms, bioinformatics analysis, and comprehensive service offerings. Their NGS platform, coupled with sophisticated bioinformatics tools and curated proprietary databases, enables them to deliver reliable results for clinical and research purposes. Moreover, their data visualization technologies make the scientific results easily understandable for everyone. In September 2020, ACT Genomics secured a Venture Round investment with participation from notable investors such as Hong Kong Science and Technology Parks Corporation, Aflac Global Ventures, and Kyoto University Innovation Capital. The company operates within the Biotechnology, Health Care, and Information Technology industries, offering clinical services including cancer prevention, early detection, treatment selection, disease monitoring, and comprehensive cancer genomic profiling and treatment options for patients with cancer. ACT Genomics also provides insights into biomarker discovery and patient stratification for clinical trials.

Business keywords: personalized medicine, genomic testing, precision medicine, cancer genomics, bioinformatics, NGS platform, cancer monitoring, immunotherapy evaluation, clinical services, cancer prevention, early detection, treatment selection, disease monitoring, oncology, molecular information

Funding Rounds & Investors (4)

View All
Funding Stage Amount Investors Lead Investors Date
Venture Round Undisclosed 3
Kyoto University Innovation Capital Co., Ltd Aflac Global Ventures
Kyoto University Innovation Capital Co., Ltd, Aflac Global Ventures +1
06 Sep 2020
Series C Undisclosed 1
CLSA Capital Partners
CLSA Capital Partners
26 Sep 2018
Series B $12.50M 1
CDIB Capital
CDIB Capital
05 May 2016
Series A $8.00M -
13 Feb 2015

ACT Genomics Alternatives & Competitors

View All Alternatives
ACT Genomics vs
IntegraGen
IntegraGen France

Company specializing in the genomics of cancer and genetic diseases

Post-IPO Equity
50 employees
Biotechnology, Health Care
Compare ACT Genomics vs IntegraGen
ACT Genomics vs
OncoDNA
OncoDNA Belgium

Genomic and theranostic company specializing in precision medicine for the treatment of cancer and g...

Series C
52 employees
Biotechnology, Health Care
Compare ACT Genomics vs OncoDNA
ACT Genomics vs
Personalis, Inc.
Personalis, Inc. United States

Ultrasensitive ctDNA testing

IPO
401 employees
Biotechnology, Health Care
Also compare with: ACT Genomics vs Geneseeq Technology Inc. Geneseeq Technology Inc. ACT Genomics vs MEDGENOME MEDGENOME ACT Genomics vs Ashion Analytics Ashion Analytics View all alternatives

FAQ About ACT Genomics

Make Personalized Medicine Accessible To All.
ACT Genomics was founded in 2014.
ACT Genomics is headquartered in Taiwan.
ACT Genomics operates in Biotechnology, Health Care, Information Technology and Clean Energy. Its work centres on personalized medicine, genomic testing, precision medicine and cancer genomics.
ACT Genomics has approximately 121 employees.
ACT Genomics has completed 4 funding rounds, raising a total of $20.50M. The latest funding stage is Venture round.
Top alternatives and competitors to ACT Genomics include IntegraGen, OncoDNA, Personalis, Inc., Geneseeq Technology Inc., MEDGENOME. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
ACT Genomics and IntegraGen are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for ACT Genomics, https://bouncewatch.com/company/act-genomics, updated 30 December 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes